Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07391774CT.gov Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | — | Recruiting | — | — | — |
NCT07610720CT.gov Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07616453CT.gov Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07483307CT.gov A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | — | Recruiting | — | — | — |
NCT07349069CT.gov A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | — | Recruiting | — | — | — |
NCT07400523CT.gov Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT06905301CT.gov Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice | — | Recruiting | — | — | — |
NCT06930859CT.gov Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia | — | Recruiting | — | — | — |
NCT07225790CT.gov Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases | — | Completed | — | — | — |
NCT07071038CT.gov Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients | — | Recruiting | — | — | — |
Show 136 more trialsShow fewer
NCT07163481CT.gov A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | — | Not Yet Recruiting | — | — | — |
NCT07101159CT.gov Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients | — | Not Yet Recruiting | — | — | — |
NCT07024173CT.gov A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07190443CT.gov Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) | — | Recruiting | — | — | — |
NCT06806930CT.gov Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | — | Recruiting | — | — | — |
NCT06492616CT.gov A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | — | Recruiting | — | — | — |
NCT06656624CT.gov Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) | — | Recruiting | — | — | — |
NCT06380751CT.gov Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06154590CT.gov Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor | — | Not Yet Recruiting | — | — | — |
NCT06341283CT.gov A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer | — | Unknown | — | — | — |
NCT06957379CT.gov Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy | — | Active Not Recruiting | — | — | — |
NCT05827081CT.gov Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | — | Recruiting | — | — | — |
NCT05896566CT.gov A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer | — | Completed | — | — | — |
NCT06375707CT.gov Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT05512364CT.gov Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | — | Recruiting | — | — | — |
NCT06016738CT.gov OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06001762CT.gov TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05952557CT.gov An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | — | Recruiting | — | — | — |
NCT05894239CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05891093CT.gov Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | — | Recruiting | — | — | — |
NCT05861830CT.gov Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) | — | Recruiting | — | — | — |
NCT05768139CT.gov First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05774951CT.gov A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | — | Recruiting | — | — | — |
NCT05780567CT.gov Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05549505CT.gov A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | — | Completed | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05645536CT.gov Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | — | Enrolling By Invitation | — | — | — |
NCT05524584CT.gov Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT04886531CT.gov Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | — | Recruiting | — | — | — |
NCT05296798CT.gov A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05161195CT.gov Roll-over Study to Allow Continued Access to Ribociclib | — | Active Not Recruiting | — | — | — |
NCT05431504CT.gov The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | — | Not Yet Recruiting | — | — | — |
NCT05472792CT.gov Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy | — | Recruiting | — | — | — |
NCT05307705CT.gov A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05257395CT.gov A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04316169CT.gov Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT04961996CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT04836520CT.gov SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. | — | Completed | — | — | — |
NCT04906395CT.gov Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04852081CT.gov Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | — | Unknown | — | — | — |
NCT04584853CT.gov PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | — | Active Not Recruiting | — | — | — |
NCT04556773CT.gov A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04553770CT.gov Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | — | Recruiting | — | — | — |
NCT04352777CT.gov Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | — | Completed | — | — | — |
NCT04436744CT.gov A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | — | Completed | — | — | — |
NCT04240106CT.gov Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | — | Completed | — | — | — |
NCT03554044CT.gov T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | — | Completed | — | — | — |
NCT04236310CT.gov A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | — | Unknown | — | — | — |
NCT04227327CT.gov Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) | — | Terminated | — | — | — |
NCT04088110CT.gov Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | — | Unknown | — | — | — |
NCT04059484CT.gov Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | — | Terminated | — | — | — |
NCT04075604CT.gov A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | — | Completed | — | — | — |
NCT03988114CT.gov A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT03966898CT.gov A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03822468CT.gov Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | — | Completed | — | — | — |
NCT04256941CT.gov Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | — | Terminated | — | — | — |
NCT03874325CT.gov Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | — | Terminated | — | — | — |
NCT03839823CT.gov Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03691493CT.gov Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | — | Completed | — | — | — |
NCT04258163CT.gov Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | — | Completed | — | — | — |
NCT04012918CT.gov Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study | — | Unknown | — | — | — |
NCT03671330CT.gov Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | — | Completed | — | — | — |
NCT04539496CT.gov A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03481998CT.gov A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT03555877CT.gov Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03179904CT.gov TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03079011CT.gov PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection | — | Completed | — | — | — |
NCT02760030CT.gov Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02476786CT.gov Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | — | Recruiting | — | — | — |
NCT02942355CT.gov Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02763566CT.gov A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02779751CT.gov A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02894398CT.gov Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | — | Completed | — | — | — |
NCT02914158CT.gov Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | — | Unknown | — | — | — |
NCT02188745CT.gov ER Reactivation Therapy for Breast Cancer | — | Completed | — | — | — |
NCT02532400CT.gov Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients | — | Terminated | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02441946CT.gov A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer | — | Completed | — | — | — |
NCT02291913CT.gov Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT02278120CT.gov Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT02246621CT.gov A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02511639CT.gov Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT02137837CT.gov S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT05800197CT.gov Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia | — | Unknown | — | — | — |
NCT02000596CT.gov 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. | — | Terminated | — | — | — |
NCT01989780CT.gov Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | — | Completed | — | — | — |
NCT02072512CT.gov The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer | — | Unknown | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01674140CT.gov S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01776008CT.gov Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | — | Terminated | — | — | — |
NCT01720602CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | — | Completed | — | — | — |
NCT02549430CT.gov To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | — | Completed | — | — | — |
NCT01791985CT.gov AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) | — | Completed | — | — | — |
NCT01597193CT.gov Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | — | Completed | — | — | — |
NCT01484041CT.gov Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01368263CT.gov Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | — | Terminated | — | — | — |
NCT01394211CT.gov Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | — | Terminated | — | — | — |
NCT01344031CT.gov MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01266213CT.gov Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women | — | Unknown | — | — | — |
NCT01153672CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | — | Completed | — | — | — |
NCT01234532CT.gov Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT01151215CT.gov Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer | — | Terminated | — | — | — |
NCT00972023CT.gov DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | — | Terminated | — | — | — |
NCT01896050CT.gov Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer | — | Completed | — | — | — |
NCT01216176CT.gov A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | — | Completed | — | — | — |
NCT00728949CT.gov A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | — | Completed | — | — | — |
NCT00738777CT.gov Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer | — | Suspended | — | — | — |
NCT00688194CT.gov Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | — | Unknown | — | — | — |
NCT00661531CT.gov Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy | — | Terminated | — | — | — |
NCT00481845CT.gov Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer | — | Terminated | — | — | — |
NCT00573755CT.gov Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00508586CT.gov PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02394496CT.gov Overcoming Endocrine Resistance in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00605267CT.gov Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment | — | Completed | — | — | — |
NCT00516542CT.gov Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00217659CT.gov S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00217399CT.gov Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00303615CT.gov Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00082277CT.gov Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT00255463CT.gov Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study | — | Completed | — | — | — |
NCT00077025CT.gov Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00081510CT.gov Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) | — | Completed | — | — | — |
NCT00057941CT.gov Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00066378CT.gov Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT00206414CT.gov Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer | — | Terminated | — | — | — |
NCT00053911CT.gov Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | — | Terminated | — | — | — |
NCT00049062CT.gov Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00235937CT.gov Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex | — | Completed | — | — | — |
NCT00186121CT.gov Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women | — | Completed | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
NCT00004900CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00004906CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00849030CT.gov ATAC - Arimidex, Tamoxifen Alone or in Combination | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anastrozole (this asset) | National Cancer Institute (NCI) | Approved | BB · 69 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Anastrozole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 74 |
| Hypogonadotropic Hypogonadism | — | P4 | BBB · 73 |
| Invasive Breast Carcinoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anastrozole in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anastrozole-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →